कंपनी का अवलोकन
Accendra Health, Inc. operates as a specialized healthcare solutions provider within the United States, focusing on delivering critical in-home care and delivery services specifically for diabetes treatment and home respiratory therapy. The company serves the broader Healthcare sector and functions specifically within the Medical Distribution industry, which involves the supply chain logistics and direct provision of essential medical equipment and therapies to patients outside of traditional hospital settings. This entity maintains a significant operational scale, employing a workforce of 6,500 individuals to support its extensive network of home care services across the nation. With a total market capitalization of $201.03 million and an annual revenue base of $2.76 billion, the company demonstrates a substantial footprint in the medical distribution landscape, suggesting it is a major player capable of influencing market dynamics despite its relatively small market cap valuation. The revenue figure indicates a robust top-line operation that generates significant volume, while the market cap suggests the current equity valuation places the company in a niche segment relative to its revenue generation capabilities.
वित्तीय स्वास्थ्य
The company reported a trailing twelve-month revenue of $2.76 billion, yet it recorded a net income loss of $102,682,000, creating a substantial gap that reveals a highly cost-structured business model where expenses significantly outweigh operating profits. Despite the negative net income, the entity generated positive EBITDA of $360.74 million, indicating that core operational cash generation remains strong before financing and non-operating expenses. The gross margin stands at 46.7%, reflecting the high value of the distributed products and services, while the operating margin of 2.9% highlights the intense competitive pressures or high fixed costs inherent in the medical distribution model. The profit margin is negative at -39.8%, confirming that for every dollar of revenue, the company loses nearly 40 cents after all expenses, including interest and taxes. However, the company possesses a free cash flow of $671.68 million, which provides considerable financial flexibility to fund operations, pay down debt, or invest in infrastructure without immediate reliance on external financing. On the balance sheet, Accendra Health holds $281.99 million in cash against total debt of $2.16 billion, indicating a heavily leveraged position where liabilities far exceed liquid assets. The debt-to-equity ratio is listed as N/A, suggesting the equity base may be negligible or the company is in a restructuring phase regarding its capital structure. The current ratio of 0.58 indicates a liquidity challenge, as current assets are less than half of current liabilities, implying potential difficulties in meeting short-term obligations without refinancing or asset sales. Furthermore, the Return on Equity is a severe -163.8%, signaling that shareholders are currently experiencing significant capital erosion, while the Return on Assets sits at 2.6%, showing that asset utilization generates minimal returns relative to the capital invested.
मूल्यांकन आकलन
The valuation metrics present a complex picture, with a trailing P/E ratio listed as N/A due to the negative net income, while the forward P/E stands at 2.53, implying that the market anticipates a potential earnings turnaround or relies on cash flow rather than current profitability for valuation. The price-to-book ratio is negative at -0.44, which indicates that the market is valuing the company at a fraction of its book value, often seen in distressed situations or when assets are not fully reflected on the balance sheet. Additionally, the price-to-sales ratio is extremely low at 0.07, suggesting the stock trades at a negligible percentage of its revenue, while the EV/EBITDA multiple of 5.77 provides an alternative valuation lens based on enterprise value relative to operating cash flow. Regarding price volatility, the stock has a 52-week high of $9.80 and a low of $1.84, meaning the current trading price sits significantly below the yearly peak, reflecting a substantial correction from recent highs. The beta value of 1.26 indicates that the stock's price is 26% more volatile than the broader market, suggesting higher risk exposure for investors during periods of market fluctuation.
Growth & Income
The company is currently experiencing a severe contraction in its top line, with revenue growth year-over-year at -73.7%, while earnings growth is N/A due to the reported net losses. The disparity between the shrinking revenue and the deep negative earnings suggests that cost reductions have not been sufficient to offset the decline in sales volume, leading to deteriorating profitability. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, meaning it does not distribute any portion of its earnings to shareholders. Instead of paying dividends, the company's capital allocation strategy focuses on retaining cash reserves, although the negative net income limits the amount available for reinvestment into growth initiatives. The overall growth and income profile is characterized by significant revenue contraction, negative profitability, and a lack of dividend income, presenting a high-risk scenario for income-focused investors.